| Dr Jason Joseph Debonis, | |
|
701 Haverford Ave, Pacific Palisades, CA 90272-4313 | |
| (917) 575-6534 | |
| Not Available |
| Full Name | Dr Jason Joseph Debonis |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 701 Haverford Ave, Pacific Palisades, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932307808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A105157 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Martin Luther King, Jr. Community Hospital | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vep Mlk Emergency Medical Group Inc | 2860707304 | 20 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Entity Name | Carbon Health Medical Group Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417294232 PECOS PAC ID: 9032340047 Enrollment ID: O20140314001276 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Entity Name | Vep Mlk Emergency Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841679289 PECOS PAC ID: 2860707304 Enrollment ID: O20150813009584 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Entity Name | Capital Hospitalist Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992178222 PECOS PAC ID: 8921308636 Enrollment ID: O20151202002282 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Entity Name | Ridgeline Emergency Physicians Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972953230 PECOS PAC ID: 0345521613 Enrollment ID: O20161228000227 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Entity Name | Corona Regional Emergency Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134629298 PECOS PAC ID: 9133481484 Enrollment ID: O20180326001396 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Joseph Debonis, 701 Haverford Ave, Pacific Palisades, CA 90272-4313 Ph: (917) 575-6534 | Dr Jason Joseph Debonis, 701 Haverford Ave, Pacific Palisades, CA 90272-4313 Ph: (917) 575-6534 |
News Archive
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
One of the most controversial topics in neurology today is the prevalence of serious permanent brain damage after traumatic brain injury. Long-term studies and a search for genetic risk factors are required in order to predict an individual's risk for serious permanent brain damage, according to a review article published by Sam Gandy, MD, PhD, from the Icahn School of Medicine at Mount Sinai in a special issue of Nature Reviews Neurology dedicated to TBI.
Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 7 days ago
Dr. Michael Dennis Flanigan, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 526 Swarthmore Ave, Pacific Palisades, CA 90272 Phone: 310-457-1079 | |
Susan Foster Reynolds, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 652 Jacon Way, Pacific Palisades, CA 90272 Phone: 800-361-5321 Fax: 310-454-4933 | |
Dr. Debra Maltenfort, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 627 Baylor St, Pacific Palisades, CA 90272 Phone: 310-936-7911 | |
Dr. John Bibb, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 16449 Akron St, Pacific Palisades, CA 90272 Phone: 310-459-3764 | |
Randall Pokomo, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Bellino Dr, Pacific Palisades, CA 90272 Phone: 310-445-9456 | |
Dr. Joseph A Hardwick, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 225 Notteargenta Rd, Pacific Palisades, CA 90272 Phone: 310-459-9965 Fax: 310-459-9965 |